Research is moving forward to adapt clinical practice to a new wave of early-onset cases of cancer in the digestive tract 

NGS testing is now recommended also for patients with some rare tumours and to detect tumour-agnostic alterations 

Study findings support routine RET-mutation testing for all patients with advanced MTC, but further work is needed to identify predictive markers